NHS Evidence - UK Database of Uncertainties about the Effects of Treatments (DUETs) - Daclizumab for relapsing remitting multiple sclerosis
Links shared publicly online about this topic.
- 448total visits
NHS Evidence - UK Database of Uncertainties about the Effects of Treatments (DUETs) - Daclizumab for relapsing remitting multiple sclerosis
The Database of Uncertainties about the Effects of Treatments (DUETs) assembles and publishes uncertainties about the effects of treatments which cannot currently be answered by referring to reliable, up-to-date systematic reviews of existing research evidence. Because inadequately evaluated treatments can do more good than harm, uncertainties about the effects of treatments must be identified and those deemed sufficiently important addressed in research.
View full resource at library.nhs.uk
Tags: Multiple Sclerosis
Most Recently Shared on March 10, 2011 at 11:53 pm By:
DUET - Daclizumab for relapsing remitting multiple sclerosis: Monoclonal antibodies such as daclizumab could be ... http://bit.ly/fA24PK
Advertisement
